Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

AZ’ Imfinzi reduces risk of death by 32% in stage III NSCLC

pharmatimesSeptember 27, 2018

Tag: AstraZeneca , Imfinzi , durvalumab

PharmaSources Customer Service